BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 Statement of Cash Flows

Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-01-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
BridgeBio Pharma, Inc. cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from issuance of preferred stock → financing reconciliation: $933,900,000.00Proceeds from issuance of 2033 Notes /2031 Notes - 2033 Notes, net → financing reconciliation: $632,500,000.00Proceeds from stock option exercises, net of repurchases → financing reconciliation: $33,712,000.00Proceeds from common stock issuances under ESPP → financing reconciliation: $9,728,000.00financing reconciliation → Net cash from financing activities: $1,264,137,000.00financing reconciliation → Repurchase of common stock: $252,502,000.00financing reconciliation → Repayments of deferred royalty obligations: $62,507,000.00financing reconciliation → Repurchase of RSU shares to satisfy tax withholding: $13,431,000.00financing reconciliation → Issuance costs and discounts associated with 2033 Notes/2031 Notes - 2033 Notes, net: $13,227,000.00financing reconciliation → Payment of preferred stock dividends: $2,694,000.00financing reconciliation → Issuance costs associated with preferred stock: $1,342,000.00Maturities of marketable securities → investing reconciliation: $76,500,000.00investing reconciliation → Net cash from investing activities: $11,761,000.00investing reconciliation → Purchases of marketable securities: $63,937,000.00investing reconciliation → Purchases of property and equipment: $802,000.00Noncash interest expense on deferred royalty obligations → operating reconciliation: $123,500,000.00Stock-based compensation → operating reconciliation: $117,171,000.00Accounts payable → operating reconciliation: $51,993,000.00Other liabilities → operating reconciliation: $48,397,000.00Net loss from equity method investments → operating reconciliation: $32,030,000.00Accrued research and development liabilities → operating reconciliation: $13,583,000.00Amortization of debt discount and issuance costs → operating reconciliation: $5,670,000.00Noncash lease expense → operating reconciliation: $4,714,000.00Depreciation and amortization → operating reconciliation: $3,308,000.00Other noncash adjustments, net → operating reconciliation: $2,233,000.00operating reconciliation → Net loss: $382,942,000.00operating reconciliation → Accounts receivable, net: $235,646,000.00operating reconciliation → Inventories: $35,641,000.00operating reconciliation → Prepaid expenses and other current assets: $26,872,000.00operating reconciliation → Accrued compensation and benefits: $9,049,000.00operating reconciliation → Change in fair value of the embedded derivative associated with the deferred royalty obligation: $7,098,000.00operating reconciliation → Deferred revenue: $6,558,000.00operating reconciliation → Other assets: $5,849,000.00operating reconciliation → Operating lease liabilities: $5,494,000.00Net cash used in operating activities → operating reconciliation: $312,550,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $572,140,000.00Net cash from financing activities → Cash sources and uses: $1,264,137,000.00Net cash from investing activities → Cash sources and uses: $11,761,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $1,535,488,000.00Cash sources and uses → Net cash used in operating activities: $312,550,000.00Net loss: -$382,942,000.00Net loss−$382.94 MStock-based compensation: $117,171,000.00Stock-based compensation+$117.17 MLoss on extinguishment of debt: $0.00Noncash interest expense on deferred royalty obligations: $123,500,000.00Noncash interest expense on deferred royaltyobligations+$123.50 MAmortization of debt discount and issuance costs: $5,670,000.00Debt cost amortization+$5.67 MDepreciation and amortization: $3,308,000.00Depreciation & amortization+$3.31 MNoncash lease expense: $4,714,000.00Operating lease amortization+$4.71 MNet loss from equity method investments: $32,030,000.00Equity-method results+$32.03 MChange in fair value of the embedded derivative associated with the deferred royalty obligation: -$7,098,000.00Embedded derivative gain & loss−$7.10 MOther noncash adjustments, net: $2,233,000.00Other non-cash items+$2.23 MAccounts receivable, net: -$235,646,000.00Accounts receivable−$235.65 MInventories: -$35,641,000.00Inventories−$35.64 MPrepaid expenses and other current assets: -$26,872,000.00Prepaid & other assets−$26.87 MOther assets: -$5,849,000.00Other operating assets−$5.85 MAccounts payable: $51,993,000.00Accounts payable+$51.99 MAccrued compensation and benefits: -$9,049,000.00Accrued compensation−$9.05 MAccrued research and development liabilities: $13,583,000.00Accrued research and development liabilities+$13.58 MOperating lease liabilities: -$5,494,000.00Operating lease liabilities−$5.49 MDeferred revenue: -$6,558,000.00Unearned revenue−$6.56 MOther liabilities: $48,397,000.00Other operating liabilities+$48.40 MNoncash income from an equity method investment: $0.00Net cash used in operating activities: -$312,550,000.00. Cash required to fund net payments.Operating cash−$312.55 Moperating reconciliation: $715,149,000.00Proceeds from issuance of 2033 Notes /2031 Notes - 2031 Notes, net: $0.00Proceeds from issuance of 2033 Notes /2031 Notes - 2033 Notes, net: $632,500,000.00Proceeds from issuance of 2033 Notes /2031 Notes -2033 Notes, net+$632.50 MIssuance costs and discounts associated with 2033 Notes/2031 Notes - 2031 Notes, net: $0.00Issuance costs and discounts associated with 2033 Notes/2031 Notes - 2033 Notes, net: -$13,227,000.00Issuance costs and discounts associated with 2033Notes/2031 Notes - 2033 Notes, net−$13.23 MRepayment of term loans: $0.00Proceeds from royalty obligation under Royalty Purchase Agreement (as described in Note 9): $0.00Issuance costs associated with royalty obligation under Royalty Purchase Agreement: $0.00Repayments of deferred royalty obligations: -$62,507,000.00Repayments of deferred royalty obligations−$62.51 MProceeds from issuance of preferred stock: $933,900,000.00Preferred stock issued+$933.90 MIssuance costs associated with preferred stock: -$1,342,000.00Stock issuance costs−$1.34 MPayment of preferred stock dividends: -$2,694,000.00Preferred dividends paid−$2.69 MRepurchase of common stock: -$252,502,000.00Common stock repurchases−$252.50 MProceeds from stock option exercises, net of repurchases: $33,712,000.00Stock option exercises+$33.71 MProceeds from common stock issuances under ESPP: $9,728,000.00Stock plan proceeds+$9.73 MRepurchase of RSU shares to satisfy tax withholding: -$13,431,000.00Stock-award tax withholding−$13.43 MTransactions with noncontrolling interests: $0.00Net cash from financing activities: $1,264,137,000.00Financing cash+$1.26 Bfinancing reconciliation: $1,609,840,000.00Purchases of marketable securities: -$63,937,000.00AFS securities purchases−$63.94 MMaturities of marketable securities: $76,500,000.00AFS securities proceeds+$76.50 MPayment for intangible assets: $0.00Purchases of property and equipment: -$802,000.00PP&E purchases−$802.00 KProceeds from special cash dividends received from an investment in equity securities: $0.00Net cash from investing activities: $11,761,000.00Investing cash+$11.76 Minvesting reconciliation: $76,500,000.00Cash sources and uses: $1,848,038,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $572,140,000.00Beginning cash$572.14 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $1,535,488,000.00Ending cash$1.54 BCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$382.94M + net operating adjustments $70.39M = operating cash −$312.55MFree cash flow−$313.35 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$963.35 MEnding cash − beginning cash
Chart details

BridgeBio Pharma, Inc. cash flow reconciliation, Jan 1, 2026 through Sep 30, 2026

Cash flows for Jan 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Dec 31, 2025. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
572,140,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
negative 312,550,000 US dollars. Net cash used.
Net loss
negative 382,942,000 US dollars
Stock-based compensation
117,171,000 US dollars
Loss on extinguishment of debt
0 US dollars
Noncash interest expense on deferred royalty obligations
123,500,000 US dollars
Amortization of debt discount and issuance costs
5,670,000 US dollars
Depreciation and amortization
3,308,000 US dollars
Noncash lease expense
4,714,000 US dollars
Net loss from equity method investments
32,030,000 US dollars
Change in fair value of the embedded derivative associated with the deferred royalty obligation
negative 7,098,000 US dollars
Other noncash adjustments, net
2,233,000 US dollars
Accounts receivable, net
negative 235,646,000 US dollars
Inventories
negative 35,641,000 US dollars
Prepaid expenses and other current assets
negative 26,872,000 US dollars
Other assets
negative 5,849,000 US dollars
Accounts payable
51,993,000 US dollars
Accrued compensation and benefits
negative 9,049,000 US dollars
Accrued research and development liabilities
13,583,000 US dollars
Operating lease liabilities
negative 5,494,000 US dollars
Deferred revenue
negative 6,558,000 US dollars
Other liabilities
48,397,000 US dollars
Noncash income from an equity method investment
0 US dollars
Investing activities
11,761,000 US dollars. Net cash provided.
Purchases of marketable securities
negative 63,937,000 US dollars
Maturities of marketable securities
76,500,000 US dollars
Payment for intangible assets
0 US dollars
Purchases of property and equipment
negative 802,000 US dollars
Proceeds from special cash dividends received from an investment in equity securities
0 US dollars
Financing activities
1,264,137,000 US dollars. Net cash provided.
Proceeds from issuance of 2033 Notes /2031 Notes - 2031 Notes, net
0 US dollars
Proceeds from issuance of 2033 Notes /2031 Notes - 2033 Notes, net
632,500,000 US dollars
Issuance costs and discounts associated with 2033 Notes/2031 Notes - 2031 Notes, net
0 US dollars
Issuance costs and discounts associated with 2033 Notes/2031 Notes - 2033 Notes, net
negative 13,227,000 US dollars
Repayment of term loans
0 US dollars
Proceeds from royalty obligation under Royalty Purchase Agreement (as described in Note 9)
0 US dollars
Issuance costs associated with royalty obligation under Royalty Purchase Agreement
0 US dollars
Repayments of deferred royalty obligations
negative 62,507,000 US dollars
Proceeds from issuance of preferred stock
933,900,000 US dollars
Issuance costs associated with preferred stock
negative 1,342,000 US dollars
Payment of preferred stock dividends
negative 2,694,000 US dollars
Repurchase of common stock
negative 252,502,000 US dollars
Proceeds from stock option exercises, net of repurchases
33,712,000 US dollars
Proceeds from common stock issuances under ESPP
9,728,000 US dollars
Repurchase of RSU shares to satisfy tax withholding
negative 13,431,000 US dollars
Transactions with noncontrolling interests
0 US dollars
Operating adjustment reconciliation
715,149,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
1,609,840,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
76,500,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Sep 30, 2026
1,535,488,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
1,848,038,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
963,348,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 312,550,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
802,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 313,352,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$382.94M + net operating adjustments $70.39M = operating cash −$312.55M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 312,550,000 US dollars minus 802,000 US dollars equals negative 313,352,000 US dollars.
BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!